Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Inclusion Criteria: * Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke - Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR) criteria * Mini-Mental State Exam (MMSE) Score between 20 \& 26 (inclusive) * CSF consistent with AD pathology * Screening brain MRI - normal - commensurate with age or demonstrate atrophy consistent with AD diagnosis (dx); reveal no more than mild white matter disease; up to 2 lacunar infarcts acceptable except in anterior thalamus, genu of internal capsule or basal forebrain; reveal no cortical infarcts; reveal no more than 4 microbleeds; reveal no focal asymmetric lobar atrophy or other findings suggesting primary cause of dementia is attributed to a cause other than AD; reveal no macrohemorrhages (\>10 mm) * Subjects must have reliable study partners * Men and Women of Non Child Bearing Potentia (WONCBP), ages 50-90 years Exclusion Criteria: * Subjects with any other medical condition other than mild AD that could explain subjects' memory or cognitive deficits * Subjects diagnosed with moderate or severe AD per DSM-IV criteria * Subjects with a history (hx) of stroke * Subjects with a hx of GI illnesses * Subjects with Vitamin B12 or folate deficiency * Subjects with any unstable cardiovascular (CV), pulmonary, Gastrointestinal (GI) or hepatic disease within 30 days prior to screening * Subjects with active liver dx or history of hepatic intolerance * Subjects with a Geriatric Depression Scale score of ≥ 6 at screening * Subjects treated for or have had a diagnosis of schizophrenia * Subjects treated for or have had a diagnosis of bipolar disease within 3 years prior to screening * Subjects with a history of generalized peripheral neuropathy